These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37581831)

  • 1. The Regulatory Landscape of New Health Technologies and Nanotechnologies: The Role of Complexity of Nanosystems.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2023; 1425():575-589. PubMed ID: 37581831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2021; 1339():317. PubMed ID: 35023119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From medical tradition to traditional medicine: A Tibetan formula in the European framework.
    Schwabl H; Vennos C
    J Ethnopharmacol; 2015 Jun; 167():108-14. PubMed ID: 25446636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Machine Learning in Centralized Authorization Process of Nanomedicines in European Union.
    Santana R; Onieva E; Zuluaga R; Duardo-Sánchez A; Gañán P
    Curr Top Med Chem; 2021; 21(9):828-838. PubMed ID: 33745436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legislation relating to nutraceuticals in the European Union with a particular focus on botanical-sourced products.
    Gulati OP; Berry Ottaway P
    Toxicology; 2006 Apr; 221(1):75-87. PubMed ID: 16487647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?
    Musazzi UM; Marini V; Casiraghi A; Minghetti P
    Drug Discov Today; 2017 Jun; 22(6):870-882. PubMed ID: 28189800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deliberating the risks of nanotechnologies for energy and health applications in the United States and United Kingdom.
    Pidgeon N; Harthorn BH; Bryant K; Rogers-Hayden T
    Nat Nanotechnol; 2009 Feb; 4(2):95-8. PubMed ID: 19197310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advanced therapy: from European regulatory framework to national regulatory framework].
    Lucas-Samuel S
    Transfus Clin Biol; 2013 May; 20(2):221-4. PubMed ID: 23517820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.